Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid

Blood

Volumn 97, Issue 1, 2001, Pages 73-80

  Douer, Dan ^a   Estey, Elihu ^b   Santillana, Sergio ^b   Bennett, John M ^b   Lopez Bernstein, Gabriel ^b   Boehm, Kristi ^b   Williams, Tony ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINOIC ACID SYNDROME;

EID: 0035169587     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.73     Document Type: Article

References (45)

1. All-trans-retinoic acid in acute promyelocytic leukemia
2. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
3. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial
4. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
5. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
6. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
7. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results
8. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases
9. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience
10. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
11. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
12. Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid
13. All-trans retinoic acid for acute promyelocytic leukemia: Results of the New York study
14. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
15. Deconstructing a disease: RARalpha, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia
16. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia
17. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia
18. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia
19. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid
20. Pharmacokinetics tissue distribution, and toxicology of tretinoin incorporated in liposomes
21. Clinical relevance of all trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia
22. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid
23. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid
24. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly-diagnosed acute promyelocytic leukemia
25. Proposals for the classification of acute leukemia
26. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17
27. Reverse transcription polymerase chain reaction for rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia
28. Regression models and life tables
29. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: Cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial
30. Presenting white cell count and kinetics of molecular remissions predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Results of the randomized MRC trial
31. Early death and anti-hemorrhagic treatment in acute promyelocytic leukemia: A GIMEMA retrospective study in 286 consecutive patients
32. Combined therapy with all trans retinoic acid and high dose chemotherapy in patients with hypoleukocytic acute promyelocytic leukemia and severe visceral hemorrhage
33. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
34. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia
35. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
36. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid
37. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia
38. AIDA (all transretinoic acid plus idarubicin) in newly diagnosed acute promyelocytic leukemia: A GIMEMA pilot study
39. The "retinoic acid syndrome" in acute promyelocytic leukemia
40. Acute promyelocytic leukemia
41. The effect of compliance with treatment on survival among patients with hematologic malignancies
42. Acute promyelocytic leukemia: From genetics to treatment
43. Molecular evaluation of residual disease as a prediction of relapse in acute promyelocytic leukemia
44. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA